HealthCare Journey for Multiple Sclerosis
  • About Us
  • Home
  • Virtual MS Center
    • Q & A for Virtual MS Center
    • Read About Our Virtual MS Center Staff
  • News & Resources
  • Seminar Registration
  • Health & Wellness
  • Blogs
    • Physician Blog >
      • Healthcare Provider Blog
    • Physical Therapy Blog
    • Patient Blog
    • Caregiver Blog
    • Research Blogs >
      • "Ask Dr. Debbie" Research Blog
      • Multiple Perspectives In Multiple Sclerosis Research Blog
  • About MS
    • What is MS?
    • Diagnosis
    • Treatment
    • MS Tips
  • Symptoms
    • Balance and Walking Issues
    • Breathing/Respiratory
    • Bowel Dysfunction
    • Cognitive Dysfunction
    • Crying/Laughing Uncontrollably (PBA)
    • Depression and Anxiety
    • Dizziness/Vertigo
    • Dysphagia
    • Fatigue
    • Foot Drop
    • Hearing or Smell or Taste Changes
    • Heat Sensitivity
    • Leg Weakness
    • Loss of Hand Dexterity and Coordination
    • Memory and Mutliple Sclerosis
    • Migraines
    • Numbness/Tingling/Altered Sensation
    • Nystagmus and Oscillopsia
    • Pain
    • Sexual Dysfunction
    • Sleep Issues
    • Spasticity/Spasms/Cramps
    • Speech/Swallowing
    • Urination/Bowel Problems
    • Vision
  • MS Clinics
  • MS Topics
    • Pregnancy and Infertility
    • Caregivers and Family Members
    • Employment and MS
    • Medical Costs and Insurance
    • Pediatric Multiple Sclerosis
  • Register With Us
  • Terms of Use/Privacy/HIPAA
  • MS HealthCare Journey

Welcome to the Virtual MS Center!

Ask any question you want about Multiple Sclerosis and one of our experts will answer it as soon as possible.
CLICK HERE TO ASK YOUR QUESTION!

What Is The Risk Of PML When Transitioning A Patient From Tysabri to Rituximab?

8/7/2014

 
Here is My Question:
What is the carryover risk of PML when transitioning a patient from Tysabri to Rituximab? Does that change how you transition?

For example, can you stop Tysabri and then start Rituximab in less than 30days (in an attempt to prevent or reduce likelihood of rebound?) OR because of lingering PML risk do you wait a certain number of days? THANKS (A neuro pharmacist)

Answer:
First, this is great that specialists treating people with MS are starting to ask questions on this site.  We want this to be a learning forum for all of us to share and learn, so there is no reason for only those with MS to ask questions here, so thanks for your question! 

To answer your question,
there is really no single answer for every case. It depends on the individual's risk of a relapse after stopping Tysabri, their JCV antibody index, their prior history of immunosuppression and their duration of Tysabri therapy.

I personally do not wait more than 60 days to treat with Rituximab so as to minimize the risk of relapse after stopping Tysabri, but this wait is often dictated by insurance authorization delays more than anything else. Most relapses after stopping Tysabri occur between 3 and 6 months following the last dose, so treating with Rituximab within 60 days is prudent. You may wait up to 3 months in a person with a lower risk of relapse and a higher risk of PML. You will definitely wait longer if there is any  concern of early pre symptomatic PML at the time of stopping Tysabri. I think it is important to repeat another MRI and possibly check CSF before starting Rituximab to make sure there is no new activity suspicious for PML.

These are of course just my thoughts on the matter. Many others in the field wait far longer than 3 months in all cases before using Rituximab after stopping Tysabri.

If you search this site for PML, you will find a lot of information about it. http://www.healthcarejourney.com/apps/search?q=PML


-Rip Kinkel, MD

PLEASE NOTE:  The information/opinions on this site should be used as an information resource only.  This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment.  Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.
Brendan W Bauer MD
2/8/2015 02:18:36 pm

Hey Rip, hope all is well. I was one of your former Residents from bright & sunny Cleveland. My question is that I have a JCV granule cell Cerebellar Degeneration that I am treating with Mirtazapine to help & block the receptor, while I am using Mefloquine to help fight the active virus. She received 88 doses of Tysabri & was one of the many who were months away from a wheelchair & literally did a 180 and dropped nearly 3.0 full points on her EDSS. Started getting trunkal ataxia 3 months ago and repeat MRI showed cerebellar vermis degeneration, although not appreciated by radiologist in very small rural Ohio. Spinal tap positive for JCV by PCR and now 2 months into therapy and had IRIS at 6 weeks treated & did very well with ACTHAR injections for 5 days. Due to how well she is doing I am going to repeat her spinal this week and check every 4 weeks until clears. Next question & more important for this site is if one survives and now nearly 70% of Tysabri are, where do we go from here. Do you play it safe and flood the system with decoys with Copaxone or in those who had devastating disease prior to Tysabri can we still use more efficacious drugs like Rituximab since they have different MOA especially when it's from T-Cell to B-cell line and thus allow some T-cytotoxic egress back into the CNS to at least fix how the problem may have started from the Tysabri side of the coin. PML is here to stay. With our success are going to come failures, but these failures of 5 years ago are just setbacks today. When do we have the bigger conversation of we can tell these patients no, but they know way too much about their disease to know when we are being cautious at their expense so we can sleep, when they are the ones living in the body and refuse not to go softly into that good night. I hope this post finds you well and generates some answers on all sides of the fence You are sorely missed by all & I welcome some comments on a very difficult but soon to be more widely discussed topic.

R Kinkel
2/14/2015 02:51:48 am

JCV granule cell neuropathy (JCV GCN) is a unique disorder described by my former colleague at Beth Israel Deaconess Medical Center, Igor Koralnik. Like progressive multifocal leukoencephalopathy (PML) it is most commonly observed in patients with lymphocyte depletion related to HIV infection or other causes. To my knowledge there are only two reported cases in Tysabri treated MS patients, both with exclusive cerebellar degeneration without evidence of typical white matter associated PML. This is in contrast to the HIV literature where JCV GCN often co-exists with typical PML. JCV GCN is associated with a novel mutation in the C terminus of the VP1 protein that does not affect the ability of the virus to replicate but does lead to preferential infection, ability to replicate or both in granule cell neurons instead of astroglial cells. Other potential JCV associated CNS infections could include JCV associated encephalopathy (preferential infection of pyramidal cell neurons) and JCV associated meningitis, both described in HIV but yet to be described in natalizumab treated patients.

I would like to know if you were able to genotype the JCV DNA isolated from the patient’s CSF to make sure it harbors a VP1 terminal deletion, since we now know that the archetypal JCV strain can circulate in the CSF of patients on natalizumab treatment without evidence of PML. It would also be important to know if rearrangements in the TCR region were detected that confer susceptibility to typical PML. Knowing the genotype will allow you to track the clearance of the neurotropic strain in the CSF.

Management of the case going forward is complex with many unanswered questions. Even if the patient demonstrated a strong CD8 response against JCV (associated with a good prognosis) and cleared neurotropic virus from the CSF, it is possible that any lymphocyte deleting drug associated with PML could lead to a recurrence. This would be particular problem with any drug associated with prolonged non-readily reversible lymphocyte depletion. I would be inclined to avoid this drugs until we learn more about the pathogenesis of JCV associated disorders. If I could not control the patient’s MS with glatiramer acetate, interferons or Gilenya (none of which have been directly associated with PML) I would possible try low dose rituximab 100 mg every 6 months, a protocol that we have found very effective in relapsing patients and associated with a more rapid return of CD19 counts prior to pretreatment.


Comments are closed.

    RSS Feed

    PLEASE NOTE: This information/opinions on this site should be used as an information source only.  This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment.  Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.
    Read About Our Virtual MS Center Authors

    Archives

    September 2024
    June 2024
    March 2024
    January 2024
    December 2023
    November 2023
    October 2023
    September 2023
    July 2023
    June 2023
    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    July 2013
    June 2013

    Categories

    All
    Accessible Housing And Environmental Modifications
    Anxiety
    Balance
    Bowel Problems
    Caregivers
    Cognitive Function
    Compliance
    David Rintell Ed. D.
    Deborah Backus Blogs
    Depression
    Diagnosis
    Diet
    Dizziness
    Dosing
    Dr. Greenberg's Q&A
    Dr. Kinkel's Q&A
    Dr. Miravalle's Q&A
    Dr. Nielsen's Q&A
    Dr. Osborne's Q&A
    Exercise
    Experimental Treatments
    Eye Surgery
    Fatigue
    Fatique
    Flu Shot
    Foot Drop
    Herbs
    Immunosuppression
    JCV
    Lasik Surgery
    Lesions
    Lori Kostich's Q&A
    Lyme Disease
    Medications
    Migraines
    Mobility
    MRI
    MS Hug
    Other Diseases
    Pain
    PML
    PPMS
    Pregnancy
    Relapse
    Safety
    Sarah Wargo's Q&A
    Sexual Dysfunction
    Side Effects
    Smoking
    Spasticity
    Stem Cell Transplantation
    Steroids
    Stress
    Supplements
    Surgery
    Symptoms
    Treatment
    Urination
    Viruses
    Vision
    Vitamin D
    Vitamins
    Weakness


© 2023 HealthCare Journey, LLC. All Rights Reserved.
HealthCare Journey™ is a trademark of HealthCare Journey, LLC
Picture
  • About Us
  • Home
  • Virtual MS Center
    • Q & A for Virtual MS Center
    • Read About Our Virtual MS Center Staff
  • News & Resources
  • Seminar Registration
  • Health & Wellness
  • Blogs
    • Physician Blog >
      • Healthcare Provider Blog
    • Physical Therapy Blog
    • Patient Blog
    • Caregiver Blog
    • Research Blogs >
      • "Ask Dr. Debbie" Research Blog
      • Multiple Perspectives In Multiple Sclerosis Research Blog
  • About MS
    • What is MS?
    • Diagnosis
    • Treatment
    • MS Tips
  • Symptoms
    • Balance and Walking Issues
    • Breathing/Respiratory
    • Bowel Dysfunction
    • Cognitive Dysfunction
    • Crying/Laughing Uncontrollably (PBA)
    • Depression and Anxiety
    • Dizziness/Vertigo
    • Dysphagia
    • Fatigue
    • Foot Drop
    • Hearing or Smell or Taste Changes
    • Heat Sensitivity
    • Leg Weakness
    • Loss of Hand Dexterity and Coordination
    • Memory and Mutliple Sclerosis
    • Migraines
    • Numbness/Tingling/Altered Sensation
    • Nystagmus and Oscillopsia
    • Pain
    • Sexual Dysfunction
    • Sleep Issues
    • Spasticity/Spasms/Cramps
    • Speech/Swallowing
    • Urination/Bowel Problems
    • Vision
  • MS Clinics
  • MS Topics
    • Pregnancy and Infertility
    • Caregivers and Family Members
    • Employment and MS
    • Medical Costs and Insurance
    • Pediatric Multiple Sclerosis
  • Register With Us
  • Terms of Use/Privacy/HIPAA
  • MS HealthCare Journey